Definitive Contract 75N93022C00029
Award Date
7/1/22
Potential Completion Date
6/30/25
Potential Value
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Neovaxsyn Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Ames, IA 50014, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,000,000.00 Small Business Innovation Research (SBIR) Phase II contract to Neovaxsyn Inc., a minority-owned, small disadvantaged business, to develop a nanovaccine for eliciting broadly neutralizing antibodies against HIV-1. The contract is a firm fixed price definitive contract with a completion date of June 30, 2027. Neovaxsyn Inc. has previously received federal funding from NIAID and the National Institute of...
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...
This is a $300,000 firm fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Neovaxsyn Inc., a minority-owned, self-certified small disadvantaged business. The contract is for the development of a next-generation immunoprevention platform against HIV-1, with a total small business set-aside. The contract award is tied to a larger Small Business Innovation Research (SBIR)...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases, valued at $299,999, was awarded to Neovaxsyn Inc. to develop a protective HIV vaccine utilizing gold nanoparticles to elicit broadly neutralizing antibodies against the fusion peptide of HIV-1 GP41. The contract was awarded under the Small Business Innovation Research Program Phase I solicitation, which sought proposals for research...
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
This is a $1,500,000.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services, to Cure Systems LLC, a self-certified small disadvantaged business located in Newton, Massachusetts. The contract is for the research and development of "Vector-Based Delivery of HIV Broadly Neutralizing Antibodies," a specialized approach to developing advanced...
This is a $600,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH), part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to develop an effective human immunodeficiency virus (HIV) vaccine using engineered nanoparticles loaded with messenger RNA (mRNA) targeted to antigen presenting cells. This contract is part of the Small Business Innovation Research (SBIR)...
This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...
This is a $299,408 SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Darwin Biosciences, Inc., a woman-owned small business. The contract is for the development of rapid diagnostic assays for self-monitoring of acute or rebound HIV-1 infection. As a Small Business Innovation Research (SBIR) award, this contract is set aside for small businesses. The contract has a firm fixed price structure and a period of performance...
This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...